| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lactation | 20 | 2026 | 77 | 4.900 |
Why?
|
| Mammary Glands, Animal | 16 | 2026 | 42 | 3.560 |
Why?
|
| Milk, Human | 11 | 2024 | 101 | 3.100 |
Why?
|
| Lipid Metabolism | 11 | 2026 | 152 | 2.660 |
Why?
|
| Obesity | 16 | 2026 | 702 | 2.610 |
Why?
|
| Fatty Acids, Omega-6 | 4 | 2025 | 22 | 1.970 |
Why?
|
| Mammary Glands, Human | 6 | 2021 | 19 | 1.930 |
Why?
|
| Fatty Acids | 11 | 2026 | 221 | 1.930 |
Why?
|
| Breast Feeding | 9 | 2024 | 99 | 1.820 |
Why?
|
| Energy Metabolism | 9 | 2026 | 216 | 1.660 |
Why?
|
| Milk | 5 | 2026 | 30 | 1.260 |
Why?
|
| Epithelial Cells | 6 | 2021 | 266 | 1.190 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2018 | 40 | 1.150 |
Why?
|
| Adipocytes | 8 | 2026 | 60 | 1.140 |
Why?
|
| Adipocytes, Beige | 2 | 2025 | 8 | 1.110 |
Why?
|
| Physical Conditioning, Animal | 2 | 2026 | 47 | 1.090 |
Why?
|
| Animals | 47 | 2026 | 10715 | 1.060 |
Why?
|
| Adipogenesis | 4 | 2025 | 27 | 1.030 |
Why?
|
| Mice | 34 | 2026 | 4815 | 1.030 |
Why?
|
| Fatty Acid Synthase, Type I | 3 | 2025 | 8 | 1.030 |
Why?
|
| Stem Cells | 2 | 2025 | 123 | 1.010 |
Why?
|
| Female | 48 | 2026 | 15690 | 1.010 |
Why?
|
| Pregnancy | 17 | 2026 | 1260 | 0.980 |
Why?
|
| Dietary Fats | 6 | 2025 | 59 | 0.920 |
Why?
|
| COUP Transcription Factor II | 1 | 2025 | 8 | 0.910 |
Why?
|
| Pediatric Obesity | 2 | 2022 | 79 | 0.860 |
Why?
|
| Mitochondria | 3 | 2024 | 410 | 0.850 |
Why?
|
| Computational Biology | 4 | 2021 | 156 | 0.850 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 56 | 0.820 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 344 | 0.800 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 58 | 0.720 |
Why?
|
| Mice, Inbred C57BL | 13 | 2026 | 1661 | 0.660 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2018 | 68 | 0.650 |
Why?
|
| Thermogenesis | 4 | 2025 | 19 | 0.640 |
Why?
|
| Adiposity | 2 | 2021 | 94 | 0.640 |
Why?
|
| Diabetes, Gestational | 1 | 2020 | 73 | 0.610 |
Why?
|
| Lipids | 4 | 2011 | 220 | 0.600 |
Why?
|
| Humans | 39 | 2026 | 28998 | 0.580 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2025 | 136 | 0.560 |
Why?
|
| Adipose Tissue | 6 | 2026 | 197 | 0.560 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2025 | 138 | 0.530 |
Why?
|
| Mothers | 3 | 2018 | 126 | 0.530 |
Why?
|
| Weight Gain | 6 | 2021 | 76 | 0.520 |
Why?
|
| Blood Glucose | 1 | 2017 | 310 | 0.480 |
Why?
|
| Transcription Factors | 4 | 2019 | 523 | 0.470 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 249 | 0.460 |
Why?
|
| Breast Neoplasms | 5 | 2026 | 483 | 0.450 |
Why?
|
| Infant | 8 | 2024 | 1049 | 0.450 |
Why?
|
| Diet, High-Fat | 6 | 2024 | 144 | 0.430 |
Why?
|
| Neocortex | 2 | 2005 | 9 | 0.430 |
Why?
|
| Male | 21 | 2026 | 13983 | 0.420 |
Why?
|
| Synaptic Transmission | 2 | 2005 | 52 | 0.420 |
Why?
|
| Neural Conduction | 2 | 2004 | 26 | 0.410 |
Why?
|
| Lipogenesis | 4 | 2019 | 29 | 0.400 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 3 | 2019 | 17 | 0.380 |
Why?
|
| Liver X Receptors | 2 | 2025 | 22 | 0.380 |
Why?
|
| Tissue Extracts | 1 | 2012 | 7 | 0.380 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 29 | 0.380 |
Why?
|
| Complex Mixtures | 1 | 2012 | 12 | 0.370 |
Why?
|
| Isotope Labeling | 1 | 2012 | 31 | 0.370 |
Why?
|
| Insulin Resistance | 2 | 2024 | 176 | 0.370 |
Why?
|
| Liver | 3 | 2025 | 471 | 0.360 |
Why?
|
| Neurons | 2 | 2005 | 297 | 0.360 |
Why?
|
| Health Promotion | 2 | 2010 | 179 | 0.360 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 466 | 0.350 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 635 | 0.350 |
Why?
|
| Docosahexaenoic Acids | 3 | 2022 | 109 | 0.350 |
Why?
|
| Prolactin | 1 | 2011 | 16 | 0.340 |
Why?
|
| Oxidative Stress | 3 | 2024 | 678 | 0.340 |
Why?
|
| Staff Development | 1 | 2010 | 9 | 0.330 |
Why?
|
| Weight Loss | 3 | 2021 | 83 | 0.330 |
Why?
|
| Community Health Services | 1 | 2010 | 34 | 0.330 |
Why?
|
| Cholesterol | 3 | 2024 | 204 | 0.320 |
Why?
|
| Gardening | 1 | 2009 | 2 | 0.310 |
Why?
|
| Urban Health | 1 | 2009 | 15 | 0.310 |
Why?
|
| Oxidation-Reduction | 2 | 2026 | 381 | 0.300 |
Why?
|
| Food Supply | 1 | 2009 | 34 | 0.300 |
Why?
|
| Triglycerides | 2 | 2025 | 123 | 0.300 |
Why?
|
| Body Composition | 4 | 2021 | 267 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2025 | 1470 | 0.300 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 117 | 0.290 |
Why?
|
| Cell Proliferation | 7 | 2026 | 825 | 0.290 |
Why?
|
| Adult | 10 | 2024 | 8048 | 0.290 |
Why?
|
| Adipose Tissue, White | 2 | 2026 | 24 | 0.290 |
Why?
|
| Postpartum Period | 2 | 2020 | 79 | 0.280 |
Why?
|
| Infant, Newborn | 6 | 2024 | 924 | 0.280 |
Why?
|
| Glucose Transporter Type 1 | 3 | 2014 | 16 | 0.280 |
Why?
|
| Energy Intake | 2 | 2019 | 69 | 0.280 |
Why?
|
| Models, Neurological | 2 | 2005 | 35 | 0.270 |
Why?
|
| Adipose Tissue, Brown | 3 | 2026 | 22 | 0.270 |
Why?
|
| Electric Stimulation | 2 | 2005 | 256 | 0.270 |
Why?
|
| Aging | 2 | 2026 | 1019 | 0.260 |
Why?
|
| Synapses | 2 | 2004 | 54 | 0.250 |
Why?
|
| RNA, Messenger | 5 | 2019 | 668 | 0.250 |
Why?
|
| Disease Models, Animal | 6 | 2025 | 1511 | 0.250 |
Why?
|
| Fatty Liver | 2 | 2025 | 77 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 329 | 0.250 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2018 | 73 | 0.250 |
Why?
|
| Adipose Tissue, Beige | 1 | 2026 | 8 | 0.240 |
Why?
|
| MicroRNAs | 2 | 2022 | 303 | 0.240 |
Why?
|
| South Africa | 4 | 2025 | 21 | 0.240 |
Why?
|
| Up-Regulation | 1 | 2006 | 247 | 0.240 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2017 | 48 | 0.230 |
Why?
|
| Cell Size | 3 | 2026 | 26 | 0.230 |
Why?
|
| Inflammation | 3 | 2026 | 668 | 0.230 |
Why?
|
| Tilapia | 1 | 2025 | 1 | 0.230 |
Why?
|
| Skin | 2 | 2024 | 153 | 0.230 |
Why?
|
| Aquaculture | 1 | 2025 | 4 | 0.230 |
Why?
|
| Solanum tuberosum | 1 | 2025 | 5 | 0.230 |
Why?
|
| Oleic Acid | 1 | 2025 | 4 | 0.230 |
Why?
|
| Dietary Supplements | 2 | 2025 | 273 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2026 | 54 | 0.220 |
Why?
|
| Muscles | 1 | 2025 | 73 | 0.220 |
Why?
|
| Indoles | 1 | 2025 | 111 | 0.220 |
Why?
|
| Phospholipids | 2 | 2022 | 76 | 0.220 |
Why?
|
| Professional Role | 1 | 2024 | 46 | 0.220 |
Why?
|
| Lipolysis | 2 | 2024 | 6 | 0.220 |
Why?
|
| Insulin | 4 | 2023 | 325 | 0.220 |
Why?
|
| Kynurenine | 1 | 2024 | 22 | 0.220 |
Why?
|
| Cytomegalovirus | 1 | 2024 | 22 | 0.210 |
Why?
|
| Animals, Newborn | 2 | 2017 | 183 | 0.210 |
Why?
|
| Diet | 3 | 2018 | 241 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 36 | 0.210 |
Why?
|
| Pharmacists | 1 | 2024 | 74 | 0.210 |
Why?
|
| Electroencephalography | 1 | 2005 | 143 | 0.210 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2017 | 129 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 170 | 0.200 |
Why?
|
| Exercise | 2 | 2023 | 498 | 0.200 |
Why?
|
| Pregnancy, Animal | 1 | 2003 | 12 | 0.200 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 88 | 0.200 |
Why?
|
| Milk Proteins | 3 | 2011 | 19 | 0.200 |
Why?
|
| Aorta | 1 | 2024 | 124 | 0.200 |
Why?
|
| Wound Healing | 1 | 2024 | 126 | 0.200 |
Why?
|
| Vasodilation | 1 | 2024 | 115 | 0.200 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2024 | 98 | 0.200 |
Why?
|
| Health Expenditures | 1 | 2023 | 30 | 0.200 |
Why?
|
| Cluster Analysis | 1 | 2003 | 127 | 0.200 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 43 | 0.200 |
Why?
|
| Clinical Competence | 1 | 2024 | 245 | 0.190 |
Why?
|
| Tight Junctions | 2 | 2017 | 29 | 0.190 |
Why?
|
| Ethers | 1 | 2022 | 5 | 0.190 |
Why?
|
| Muscle, Skeletal | 3 | 2023 | 641 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 75 | 0.190 |
Why?
|
| Phosphatidylethanolamines | 1 | 2022 | 26 | 0.190 |
Why?
|
| Premature Birth | 1 | 2023 | 58 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2021 | 415 | 0.190 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 292 | 0.190 |
Why?
|
| Pharmacy | 1 | 2023 | 36 | 0.190 |
Why?
|
| Rats | 5 | 2023 | 1592 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2022 | 89 | 0.180 |
Why?
|
| PPAR gamma | 2 | 2022 | 29 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2024 | 191 | 0.180 |
Why?
|
| Endothelium, Vascular | 1 | 2024 | 334 | 0.170 |
Why?
|
| Lipoprotein Lipase | 1 | 2021 | 10 | 0.170 |
Why?
|
| Oleic Acids | 1 | 2021 | 4 | 0.170 |
Why?
|
| Adiponectin | 2 | 2018 | 29 | 0.170 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 6 | 0.170 |
Why?
|
| Arachidonic Acid | 2 | 2018 | 19 | 0.170 |
Why?
|
| Overweight | 1 | 2022 | 114 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 51 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 472 | 0.160 |
Why?
|
| Mice, Transgenic | 5 | 2018 | 514 | 0.160 |
Why?
|
| Smad4 Protein | 1 | 2020 | 5 | 0.160 |
Why?
|
| Myofibroblasts | 1 | 2020 | 23 | 0.160 |
Why?
|
| Estrous Cycle | 1 | 2019 | 5 | 0.160 |
Why?
|
| Research Design | 1 | 2021 | 188 | 0.160 |
Why?
|
| Murine hepatitis virus | 1 | 2019 | 1 | 0.150 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2019 | 1 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2020 | 292 | 0.150 |
Why?
|
| Perilipin-1 | 2 | 2017 | 3 | 0.150 |
Why?
|
| Leptin | 2 | 2018 | 67 | 0.150 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 12 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 38 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 82 | 0.150 |
Why?
|
| Cytoplasm | 2 | 2011 | 57 | 0.150 |
Why?
|
| Body Weight Maintenance | 1 | 2019 | 2 | 0.150 |
Why?
|
| Ovary | 1 | 2019 | 72 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2018 | 104 | 0.150 |
Why?
|
| Epithelium | 1 | 2019 | 40 | 0.150 |
Why?
|
| Cold Temperature | 1 | 2019 | 35 | 0.150 |
Why?
|
| Uncoupling Protein 1 | 3 | 2026 | 22 | 0.150 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 50 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 413 | 0.140 |
Why?
|
| Transgenes | 1 | 2018 | 63 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 93 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 10 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2019 | 49 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2010 | 515 | 0.140 |
Why?
|
| Fertility | 1 | 2018 | 60 | 0.140 |
Why?
|
| Reproduction | 1 | 2018 | 64 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 90 | 0.140 |
Why?
|
| Estrogens | 1 | 2018 | 56 | 0.140 |
Why?
|
| Motor Activity | 1 | 2019 | 148 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 17 | 0.140 |
Why?
|
| alpha-Linolenic Acid | 1 | 2017 | 5 | 0.130 |
Why?
|
| Trophoblasts | 1 | 2017 | 14 | 0.130 |
Why?
|
| Child Development | 1 | 2018 | 79 | 0.130 |
Why?
|
| Claudins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Glucose | 5 | 2022 | 209 | 0.130 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Phenotype | 1 | 2019 | 687 | 0.130 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2016 | 3 | 0.130 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 18 | 0.130 |
Why?
|
| Colorado | 1 | 2016 | 51 | 0.130 |
Why?
|
| Metformin | 1 | 2017 | 36 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2010 | 485 | 0.130 |
Why?
|
| Rats, Wistar | 3 | 2023 | 153 | 0.120 |
Why?
|
| Birth Weight | 1 | 2016 | 63 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2017 | 153 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 344 | 0.120 |
Why?
|
| Child | 1 | 2022 | 2327 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 433 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 194 | 0.120 |
Why?
|
| Risk Factors | 2 | 2017 | 2134 | 0.110 |
Why?
|
| Membrane Potentials | 2 | 2005 | 65 | 0.110 |
Why?
|
| Models, Biological | 2 | 2007 | 469 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 1619 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1004 | 0.110 |
Why?
|
| Glycolysis | 2 | 2014 | 96 | 0.110 |
Why?
|
| Cats | 2 | 2005 | 52 | 0.110 |
Why?
|
| Potassium | 2 | 2005 | 43 | 0.110 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 58 | 0.110 |
Why?
|
| Catalysis | 1 | 2014 | 133 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2026 | 1351 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 112 | 0.100 |
Why?
|
| United States | 3 | 2024 | 2247 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 465 | 0.100 |
Why?
|
| Enzyme Assays | 1 | 2012 | 6 | 0.090 |
Why?
|
| Palmitic Acid | 1 | 2012 | 11 | 0.090 |
Why?
|
| Carbon Isotopes | 1 | 2012 | 43 | 0.090 |
Why?
|
| NADP | 1 | 2012 | 39 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2010 | 206 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2025 | 34 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2012 | 151 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 211 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2016 | 1022 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2014 | 876 | 0.090 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2011 | 21 | 0.090 |
Why?
|
| Bromocriptine | 1 | 2011 | 2 | 0.090 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2011 | 12 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2011 | 6 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 686 | 0.090 |
Why?
|
| Growth | 1 | 2011 | 24 | 0.090 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 33 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 417 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 1011 | 0.080 |
Why?
|
| Professional Competence | 1 | 2010 | 38 | 0.080 |
Why?
|
| Apoptosis | 2 | 2020 | 780 | 0.080 |
Why?
|
| Rural Health Services | 1 | 2010 | 26 | 0.080 |
Why?
|
| Feces | 2 | 2024 | 117 | 0.080 |
Why?
|
| Leadership | 1 | 2010 | 55 | 0.080 |
Why?
|
| Placenta | 2 | 2023 | 78 | 0.080 |
Why?
|
| Poverty | 1 | 2010 | 90 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 88 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2010 | 274 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2009 | 162 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 176 | 0.070 |
Why?
|
| Gene Expression | 1 | 2010 | 417 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2008 | 9 | 0.070 |
Why?
|
| Recurrence | 2 | 2019 | 327 | 0.070 |
Why?
|
| Prognosis | 2 | 2021 | 812 | 0.070 |
Why?
|
| Animal Feed | 1 | 2007 | 21 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 285 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 80 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 310 | 0.070 |
Why?
|
| Breast | 1 | 2007 | 52 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1032 | 0.070 |
Why?
|
| Cell Line | 3 | 2019 | 701 | 0.070 |
Why?
|
| Protein Kinase C | 1 | 2007 | 74 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 314 | 0.060 |
Why?
|
| Proteome | 1 | 2007 | 81 | 0.060 |
Why?
|
| Cytokines | 2 | 2019 | 452 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 431 | 0.060 |
Why?
|
| Indoleacetic Acids | 1 | 2025 | 16 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2018 | 79 | 0.060 |
Why?
|
| Hepatic Stellate Cells | 1 | 2025 | 23 | 0.060 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2025 | 12 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2006 | 79 | 0.060 |
Why?
|
| Ceramides | 1 | 2025 | 33 | 0.060 |
Why?
|
| Maternal Exposure | 1 | 2025 | 29 | 0.060 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Middle Aged | 2 | 2024 | 7428 | 0.060 |
Why?
|
| Normal Distribution | 1 | 2005 | 8 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 37 | 0.060 |
Why?
|
| Electric Conductivity | 1 | 2005 | 20 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2005 | 24 | 0.060 |
Why?
|
| Fibrosis | 1 | 2026 | 143 | 0.060 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2025 | 35 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2020 | 332 | 0.060 |
Why?
|
| Diet, Western | 1 | 2025 | 45 | 0.060 |
Why?
|
| Neural Inhibition | 1 | 2005 | 48 | 0.060 |
Why?
|
| 3T3-L1 Cells | 1 | 2025 | 30 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 33 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2026 | 190 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 278 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2025 | 29 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2006 | 268 | 0.060 |
Why?
|
| Social Theory | 1 | 2024 | 2 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 6 | 0.050 |
Why?
|
| Decanoic Acids | 1 | 2024 | 2 | 0.050 |
Why?
|
| Electricity | 1 | 2004 | 7 | 0.050 |
Why?
|
| Viral Load | 1 | 2024 | 32 | 0.050 |
Why?
|
| Tryptophan | 1 | 2024 | 42 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2024 | 27 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2004 | 80 | 0.050 |
Why?
|
| Fructose | 1 | 2024 | 22 | 0.050 |
Why?
|
| Aldehydes | 1 | 2024 | 55 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2025 | 157 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2024 | 25 | 0.050 |
Why?
|
| Sucrose | 1 | 2023 | 27 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2025 | 585 | 0.050 |
Why?
|
| Metabolome | 1 | 2024 | 70 | 0.050 |
Why?
|
| Basal Metabolism | 1 | 2023 | 11 | 0.050 |
Why?
|
| Sensory Thresholds | 1 | 2003 | 14 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 1 | 2003 | 31 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2003 | 10 | 0.050 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2003 | 9 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2003 | 62 | 0.050 |
Why?
|
| Dendrites | 1 | 2003 | 25 | 0.050 |
Why?
|
| Schools, Pharmacy | 1 | 2023 | 33 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 135 | 0.050 |
Why?
|
| Sodium | 1 | 2003 | 50 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2024 | 155 | 0.050 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 124 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 175 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 43 | 0.050 |
Why?
|
| Action Potentials | 1 | 2003 | 196 | 0.050 |
Why?
|
| Parents | 1 | 2023 | 142 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 50 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 205 | 0.040 |
Why?
|
| Massachusetts | 1 | 2021 | 18 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 307 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 788 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 22 | 0.040 |
Why?
|
| Phthalazines | 1 | 2020 | 25 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 50 | 0.040 |
Why?
|
| Aged | 1 | 2009 | 5608 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2019 | 25 | 0.040 |
Why?
|
| Running | 1 | 2019 | 39 | 0.040 |
Why?
|
| Photoperiod | 1 | 2019 | 4 | 0.040 |
Why?
|
| Benzylamines | 1 | 2019 | 19 | 0.040 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 10 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 38 | 0.040 |
Why?
|
| Benzoates | 1 | 2019 | 30 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 94 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 275 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2019 | 74 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 67 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2018 | 8 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 257 | 0.040 |
Why?
|
| Ghrelin | 1 | 2018 | 7 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 4 | 0.040 |
Why?
|
| Adipocytes, White | 1 | 2018 | 10 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 28 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1283 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 306 | 0.030 |
Why?
|
| Organic Cation Transporter 2 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 430 | 0.030 |
Why?
|
| Fetus | 1 | 2017 | 79 | 0.030 |
Why?
|
| Phosphoproteins | 2 | 2007 | 120 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 195 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 65 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 479 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 470 | 0.030 |
Why?
|
| Lactobacillales | 1 | 2016 | 2 | 0.030 |
Why?
|
| Gammaproteobacteria | 1 | 2016 | 11 | 0.030 |
Why?
|
| Fatty Acids, Volatile | 1 | 2016 | 15 | 0.030 |
Why?
|
| Plethysmography | 1 | 2016 | 27 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 202 | 0.030 |
Why?
|
| Pyruvate Kinase | 1 | 2016 | 13 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 110 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 204 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 490 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 303 | 0.030 |
Why?
|
| Fatty Acid Synthases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2014 | 4 | 0.030 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 48 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2007 | 427 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 164 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 35 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 47 | 0.030 |
Why?
|
| Colitis | 1 | 2014 | 54 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 898 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 782 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 419 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 124 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 270 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 91 | 0.020 |
Why?
|
| Schools | 1 | 2010 | 90 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2010 | 66 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 97 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 159 | 0.020 |
Why?
|
| Matrix Metalloproteinase 11 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 76 | 0.020 |
Why?
|
| Myometrium | 1 | 2008 | 7 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 34 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 24 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 78 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 147 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Occludin | 1 | 2007 | 12 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2007 | 17 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2007 | 35 | 0.020 |
Why?
|
| Perilipin-2 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Perilipin-3 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 589 | 0.020 |
Why?
|
| Lactose | 1 | 2007 | 7 | 0.020 |
Why?
|
| Protein Transport | 1 | 2007 | 158 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2007 | 115 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2007 | 238 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2007 | 256 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 871 | 0.010 |
Why?
|